- Tel: 858.663.9055
-
Email: info@nsjbio.com
- Tel: 858.663.9055
- Email: info@nsjbio.com
Related Products
|
RARA Antibody / Retinoic Acid Receptor Alpha Antibody recognizes a ligand-dependent nuclear receptor encoded by the RARA gene. Retinoic acid receptor alpha belongs to the nuclear receptor superfamily and functions as a transcription factor that regulates gene expression in response to retinoic acid, a biologically active derivative of vitamin A. RARA contributes to embryonic development, cellular differentiation, proliferation, and tissue homeostasis through its control of retinoic acid-responsive genes.
RARA typically forms heterodimers with retinoid X receptors (RXRs), allowing the complex to bind specific DNA sequences known as retinoic acid response elements (RAREs). In the absence of an activating ligand, RARA-RXR complexes can recruit transcriptional corepressors and histone deacetylases, maintaining target genes in a relatively repressed state. Binding of all-trans retinoic acid promotes conformational changes that favor the release of corepressors and recruitment of transcriptional coactivators. These interactions help coordinate chromatin remodeling and transcriptional activation in response to developmental and physiological signals.
Retinoic acid signaling is particularly important during hematopoietic differentiation, including the maturation of granulocytic cells. RARA regulates transcriptional programs that influence the transition from immature progenitors to differentiated cell populations. Its activity also contributes to epithelial differentiation, nervous system development, and the maintenance of tissue-specific gene expression. Alternative promoter usage and transcript processing generate RARA isoforms with distinct regulatory regions, potentially influencing receptor expression and transcriptional responses in different cellular contexts.
RARA is closely associated with acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia characterized by impaired myeloid differentiation. The PML::RARA fusion protein, produced by the t(15;17) chromosomal translocation, disrupts normal retinoic acid-dependent transcriptional regulation and contributes to the accumulation of abnormal promyelocytes. Pharmacological concentrations of all-trans retinoic acid can overcome aspects of this differentiation block, forming an important component of APL treatment. Additional RARA rearrangements involving other fusion partners have also been described. NSJ Bioreagents offers this RARA Antibody for investigating nuclear receptor signaling, transcriptional regulation, and the molecular mechanisms underlying retinoid-dependent differentiation.
Explore additional antibodies targeting nuclear receptors, transcriptional regulators, and proteins involved in ligand-dependent signaling in our Signal Transduction Antibodies collection.
The stated application concentrations are suggested starting points. Titration of the RARA Antibody / Retinoic Acid Receptor Alpha Antibody may be required due to differences in protocols and secondary/substrate sensitivity.
A portion of amino acids 322-349 from the human protein were used as the immunogen for the RAR alpha antibody.
Aliquot the RARA Antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.
RAR alpha antibody, Retinoic acid receptor alpha antibody, Nuclear receptor subfamily 1 group B member 1 antibody, NR1B1 antibody
Your bulk quote request has been submitted successfully!
Please contact us if you have any questions.